|Institutional Source||Beutler Lab|
|Gene Name||CBP80/20-dependent translation initiation factor|
|Is this an essential gene?||Probably non essential (E-score: 0.128)|
|Stock #||R7765 (G1)|
|Chromosomal Location||75431224-75697696 bp(-) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to T at 75605644 bp|
|Amino Acid Change||Valine to Aspartic acid at position 164 (V164D)|
|Ref Sequence||ENSEMBL: ENSMUSP00000129974 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000165559]|
|Predicted Effect||probably damaging
AA Change: V164D
PolyPhen 2 Score 0.999 (Sensitivity: 0.14; Specificity: 0.99)
AA Change: V164D
|Meta Mutation Damage Score||0.5069|
|Coding Region Coverage||
|Validation Efficiency||100% (62/62)|
|MGI Phenotype||FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] CTIF is a component of the CBP80 (NCBP1; MIM 600469)/CBP20 (NCBP2; MIM 605133) translation initiation complex that binds cotranscriptionally to the cap end of nascent mRNA. The CBP80/CBP20 complex is involved in a simultaneous editing and translation step that recognizes premature termination codons (PTCs) in mRNAs and directs PTC-containing mRNAs toward nonsense-mediated decay (NMD). On mRNAs without PTCs, the CBP80/CBP20 complex is replaced with cytoplasmic mRNA cap-binding proteins, including EIF4G (MIM 600495), and steady-state translation of the mRNAs resumes in the cytoplasm (Kim et al., 2009 [PubMed 19648179]).[supplied by OMIM, Dec 2009]|
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ctif||
(F):5'- TATTACCAAGGTGGGTTGTCC -3'
(R):5'- TCATTCGCTGGGAGCTTAACAG -3'
(F):5'- GTCCCAATCATTGTCAGTGACACAG -3'
(R):5'- CTTAACAGCTGGGCCTAGAAG -3'